Privia Health Group (PRVA) Stock Price, News & Analysis

Company Overview

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.

Key Stats

• Today's Range: $23.33 to $24.11
• 50-Day Range: $19.96 to $25.69
• 52-Week Range: $15.92 to $26.04
• Volume: 650,834 shs
• Average Volume: 756,126 shs
• Market Capitalization: $2.82 billion
• P/E Ratio: 233.82
• Dividend Yield: N/A
• Price Target: $26.67
• Consensus Rating: Buy

Privia Health Group Stock Analysis - MarketRank™

Privia Health Group scored higher than 79% of companies evaluated by MarketBeat, and ranked 219th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Privia Health Group has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Privia Health Group has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 92.86%

Earnings Growth

Earnings for Privia Health Group are expected to grow by 92.86% in the coming year, from $0.14 to $0.27 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Privia Health Group is 233.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.15.

Price to Earnings Ratio vs. Sector

The P/E ratio of Privia Health Group is 233.36, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.65.

Price to Earnings Growth Ratio

Privia Health Group has a PEG Ratio of 3.47. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Privia Health Group has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.88% of the float of Privia Health Group has been sold short.

Short Interest Ratio / Days to Cover

Privia Health Group has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Privia Health Group has recently decreased by 11.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Privia Health Group does not currently pay a dividend.

Dividend Growth

Privia Health Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.88% of the float of Privia Health Group has been sold short.

Short Interest Ratio / Days to Cover

Privia Health Group has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Privia Health Group has recently decreased by 11.16%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.77

News Sentiment

Privia Health Group has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Privia Health Group this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for PRVA on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Privia Health Group to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Privia Health Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.20% of the stock of Privia Health Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.48% of the stock of Privia Health Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRVA Stock Analysis - Frequently Asked Questions

How have PRVA shares performed this year?

Privia Health Group's stock was trading at $19.55 at the start of the year. Since then, PRVA shares have increased by 19.4% and is now trading at $23.3340.
View the best growth stocks for 2025 here.

How were Privia Health Group's earnings last quarter?

Privia Health Group, Inc. (NASDAQ:PRVA) issued its earnings results on Thursday, August, 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by $0.02. The company's quarterly revenue was up 2.2% on a year-over-year basis.

When did Privia Health Group IPO?

Privia Health Group (PRVA) raised $351 million in an initial public offering on Thursday, April 29th 2021. The company issued 19,500,000 shares at $17.00-$19.00 per share. Goldman Sachs, J.P. Morgan, Credit Suisse, Piper Sandler and William Blair served as the underwriters for the IPO and Canaccord Genuity, Truist Securities, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

Who are Privia Health Group's major shareholders?

Top institutional shareholders of Privia Health Group include FMR LLC (15.17%), Durable Capital Partners LP (9.57%), Vanguard Group Inc. (9.52%) and Riverbridge Partners LLC (4.85%). Insiders that own company stock include Adam Boehler, William M Sullivan, Jeffrey B Butler, David Mountcastle, Parth Mehrotra, Advisors LLC Mbd, Thomas Bartrum, Matthew Shawn Morris and Thomas A Mccarthy.
View institutional ownership trends.

How do I buy shares of Privia Health Group?

Shares of PRVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Privia Health Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Privia Health Group investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 3/13/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PRVA
• CIK: 1759655
• Web: www.priviahealth.com
• Phone: 571-366-8850
• Fax: N/A
• Employees: 1,102
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $26.67
• High Stock Price Target: $40.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +13.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.06
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.11
• Trailing P/E Ratio: 234.72
• Forward P/E Ratio: 167.90
• P/E Growth: 3.47
• Net Income: $23.08 million
• Net Margins: 0.75%
• Pretax Margin: 1.41%
• Return on Equity: 2.02%
• Return on Assets: 1.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.78
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $1.74 billion
• Price / Sales: 1.63
• Cash Flow: $0.24 per share
• Price / Cash Flow: 98.24
• Book Value: $5.14 per share
• Price / Book: 4.57

Miscellaneous

• Outstanding Shares: 120,513,000
• Free Float: 102,961,000
• Market Cap: $2.83 billion
• Optionable: Optionable
• Beta: 0.85